Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002195 · ClinicalTrials.gov registry record · Phase 3
A Study of Retrovir and Epivir Alone or in Combination With 141W94 in HIV-Infected Patients
A Phase 3 study, sponsored by Glaxo Wellcome.
- Completed
- Registry status
- Phase 3
- Development phase
- 290
- Enrollment target
NCT00002195: Completed Phase 3 study, sponsored by Glaxo Wellcome.
NCT00002195 is a Phase 3 study that has completed, run by Glaxo Wellcome. The registered enrollment target is 290 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (62% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002195, a Phase 3 study, has completed, sponsored by Glaxo Wellcome.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 290 participants
- Enrollment target
Study Summary
The purpose of this study is to see if it is safe and effective to add 141W94 to an anti-HIV regimen that includes retrovir plus epivir.
Interventions
- DRUG Zidovudine
- DRUG Lamivudine
- DRUG Amprenavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 290 participants |
| Phase | Phase 3 |
What the finished NCT00002195 record still lists
NCT00002195 is an interventional study that assigns participants to a tested intervention. The registered 290 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (62% lower).
The record links to 0 conditions, and to 3 interventions - of which Zidovudine is the first listed.
NCT00002195 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002195 about?
NCT00002195 is a clinical study titled "A Study of Retrovir and Epivir Alone or in Combination With 141W94 in HIV-Infected Patients". The purpose of this study is to see if it is safe and effective to add 141W94 to an anti-HIV regimen that includes retrovir plus epivir.
What is the current status of trial NCT00002195?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 290 participants.
What interventions are being tested in trial NCT00002195?
The interventions under investigation include: Zidovudine (DRUG), Lamivudine (DRUG), Amprenavir (DRUG).
Who is sponsoring clinical trial NCT00002195?
This trial is sponsored by Glaxo Wellcome, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00002195's enrollment target sits among peer trials
290 1171st of 2000 higher than 828 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00775476 · 290 participants · Phase 2
Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine
- NCT01874197 · 290 participants · NA
Branched Thoracic Endovascular Grafts for the Treatment of Thoraco-abdominal Aortic
- NCT04331353 · 290 participants · NA
The Allergen Reduction and Child Health Study (ARCHS)
- NCT04649008 · 290 participants · Early Phase 1
Localizing Epileptic Networks Using MRI and iEEG